Taconic Launches FcResolv® NOG-EXL Mouse Models to Support Superior Antibody-Based Drug Studies

Taconic Biosciences has launched the industry’s first and only platform with FcgR knockout that enables more precise and expedited immuno-oncology preclinical research outcomes.

The FcResolv® NOG-EXL mouse model, which lacks Fc gamma receptors (FcgR), overcomes a previous challenge that has been known to delay the advancement of translational research. The presence of Fc receptors, found on both human and murine cells, can lead to confounding effects and inaccurate conclusions within the context of immunology and antibody-based drug studies. 

Two prior versions of Taconic superimmunodeficient FcgR knockout models were launched in 2022 (FcResolv® NOG and FcResolv® hIL-15 NOG models) and have been widely recognized for their unique capabilities to improve experimental accuracy in murine models. The newest addition to the FcResolv® family further represents a critical advancement with particular utility for acute myelogenous leukemia (AML) research.

Built on the powerful NOG super immunodeficient mouse platform, the FcResolv NOG-EXL mouse models: 

  • Prevent Fc gamma receptor interference that can lead to false positives or false negatives
  • Express human IL-3 and GM-CSF to enable consistent human myeloid cell reconstitution
  • Are ideal for studies of antibody-based therapeutics with potential for Fc domain interference
  • Are available as humanized immune system (HIS) models engrafted with CD34+ HSCs

“This model is a gamechanger for scientists in both academia and in pharma,” remarks Louise Baskin, Senior Director, New Product Pipeline, adding, “it eliminates the interference of Fc gamma receptors in drug efficacy studies in a highly translatable mouse model. Ultimately, this means more accurate testing and a faster timeline to an effective therapeutic."

Featured Models

FcResolv® NOG Portfolio

View all models in the FcResolv® NOG Portfolio

View
webinar

Resource

NOG-EXL mouse model from Taconic outperforms NSG-SGM3 in new study

Read about the new paper from scientists at the University of Pennsylvania and Taconic showing improved outcomes in glioblastoma research using the NOG-EXL mouse model.
Read More

About Taconic Biosciences, Inc.
Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contacts:

For marketing inquiries:

George Goodno, Director Marketing Communications

marketing@taconic.com

For scientific inquiries:

Moriah Jacobson, PhD,
Field Applications Scientist

moriah.jacobson@taconic.com

Schedule A Scientific Consultation

Speak with a PhD-level Field Application Scientist who can help you select the most appropriate model and maximize your experimental success.